The number behind the headline: 2,525 people
A 2023 review combined 50 human studies of inulin, covering a total of 2,525 people, and the pooled measurement centred on beneficial gut bacteria populations before and after inulin intake.
Pooling 50 separate studies means combining different countries, different age groups, and different lengths of intake into one dataset. The 2,525 figure is a sum, not a single trial, so it reflects variety in method as much as consistency in outcome.
What the review measured was a shift in specific bacterial groups, detected through stool sampling and lab analysis. It did not measure how participants felt, what they ate otherwise, or any outcome beyond the bacterial counts themselves.
What counts as a measurement versus a claim
A measurement is a number produced by a specific method: a stool sample analysed for particular bacterial species, recorded before and after a period of inulin intake. That is what the 2023 review aggregated.
A claim is what someone does with that number afterwards. The review itself did not conclude that inulin does anything to a person beyond the bacterial shift it recorded in those 2,525 participants.
This distinction matters because bacterial population changes in a lab sample are not the same as any outcome a reader might assume from the word 'beneficial'. The review used that word to describe bacteria types already associated with fermentation activity in the gut, not to describe any effect on the person supplying the sample.
Why 50 studies is both a strength and a limit
Having 50 studies to pool is a genuine strength: it reduces the chance that one unusual result drives the overall pattern, since single-study anomalies get diluted across a larger dataset.
But 50 is also a ceiling. It tells you how many studies existed and met inclusion criteria at the time of the 2023 review, not how many exist now, and not whether every study measured the same bacterial groups in the same way.
Reviews like this also depend on what got published. A study that found no change in bacterial counts is less likely to appear in journals than one that found a shift, which can tilt a pooled figure like 2,525 toward positive-sounding results even when methods vary widely.
Where inulin sits in a five-fibre blend
Inulin makes up 7% of the BIOMEWARD blend, a lemon-flavoured Australian prebiotic fibre powder sold in a 165 g pouch of 30 serves. It is the fastest-fermenting of the blend's five fibres, alongside PHGG, psyllium, resistant potato starch and acacia.
That fermentation speed is a laboratory characteristic, measured in how quickly gut bacteria break the fibre down, not a claim about how a person will experience it. The 2023 review's 2,525 participants were measured on inulin specifically, not on blends combining it with slower-fermenting fibres.
Reading a study like this is useful for understanding what one ingredient does in isolation under test conditions. It is less useful for predicting what happens when that ingredient sits at 7% of a broader mix, since the review wasn't built to answer that question.